ARS Pharmaceuticals’ (SPRY) Outperform Rating Reiterated at William Blair
William Blair reaffirmed their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a research report sent to investors on Friday,RTT News reports. A number of other brokerages have also recently weighed in on SPRY. Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave […]
William Blair reaffirmed their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a research report sent to investors on Friday,RTT News reports. A number of other brokerages have also recently weighed in on SPRY. Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave […]
